A meta-analysis of anti-CTLA-4, anti-PD-1/PD-L1 treatments that included 37 randomized controlled studies found that 194 of 7531 patients developed hyperthyroidism and 472 of 7551 patients developed hypothyroidism 102. The gene discussed is CTLA4; the disease is hypothyroidism.